Neurocrine Biosciences (NBIX) Change in Accured Expenses (2010 - 2026)

Neurocrine Biosciences has reported Change in Accured Expenses for 17 years, with the latest figure at -$14.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 376.67% year-over-year to -$14.3 million; the trailing twelve-month figure through Mar 2026 stood at $148.9 million (up 152.37% YoY), and the FY2025 full-year result was $160.2 million, up 269.12% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$14.3 million, down from $76.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $124.4 million in Q3 2023, with the low at -$98.3 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged $20.8 million across 5 years, with a median of $30.9 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 279.27% — and 2024, when it plunged 467.28%.
• Neurocrine Biosciences' Change in Accured Expenses stood at $37.6 million in 2022, then slumped by 361.44% to -$98.3 million in 2023, then jumped by 178.64% to $77.3 million in 2024, then retreated by 1.03% to $76.5 million in 2025, then sank by 118.69% to -$14.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$14.3 million (Q1 2026), $76.5 million (Q4 2025), and $55.8 million (Q3 2025), per Business Quant data.